FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1923935917> ?p ?o ?g. }

• W1923935917 endingPage "725" @default.
• W1923935917 startingPage "719" @default.
• W1923935917 abstract "To determine long-term outcome of intraocular antagonism of vascular endothelial growth factor (VEGF) in macular oedema (ME) secondary to branch retinal vein occlusion (BRVO).A total of 28 consecutive patients were treated with either intravitreal bevacizumab (IVB) or intravitreal ranibizumab (IVR) in the first series and were evaluated after a mean follow-up of 5 years for their functional and anatomical outcome.Time between onset of macular oedema and initial treatment was 5.2 ± 0.4/0.1 ± 0.1 (IVB/IVR) months. A mean of 4 intravitreal injections were given per patients in the first 6 months. In months 7-12 intravitreal injections decreased to 2 and further decreased in the second year (months 13-18: 1.14; months 19-24: 0.5) and third year (months 25-30: 0.4; months 31-36: 0.2). After the fourth year, only two of the 28 patients received further treatment. Average visual acuity (VA) increased by 16 letters after 1 year (p < 0.01) and although not statistically significantly, by a mean of 5 letters (p = 0.3) at long-term evaluation (IVB-group). However, after mean of 5 years, central retinal sensitivity (CRS) improved by 3.6 dB (p = 0.01) and central retinal thickness (CRT) decreased by 161 μm (p = 0.02). In the IVR-group, VA and CRS increased significantly (31 letters and respectively 4.4 dB, p < 0.001) and CRT decreased by 229 μm (p < 0.001) after long-term follow-up. Final functional results were significantly better in patients with treatment initiation <3 months (79 versus 55 letters, p = 0.01). Microvascular abnormalities were detected in 88% (21 of 24 patients), hyperfluorescence in 42% (10 of 24 patients) on wide-field fluorescein angiography in both groups.Inhibition of VEGF provides substantial long-term benefits for patients with ME secondary to BRVO. Early treatment with anti-VEGF agents and extended therapeutic surveillance was associated with improved visual recovery." @default.
• W1923935917 created "2016-06-24" @default.
• W1923935917 creator A5003153143 @default.
• W1923935917 creator A5038462897 @default.
• W1923935917 creator A5038801101 @default.
• W1923935917 creator A5044151832 @default.
• W1923935917 creator A5053563726 @default.
• W1923935917 creator A5073684856 @default.
• W1923935917 date "2015-06-24" @default.
• W1923935917 modified "2023-10-06" @default.
• W1923935917 title "Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years" @default.
• W1923935917 cites W1968756919 @default.
• W1923935917 cites W1983275936 @default.
• W1923935917 cites W1984090235 @default.
• W1923935917 cites W1986085253 @default.
• W1923935917 cites W1997777727 @default.
• W1923935917 cites W2000661411 @default.
• W1923935917 cites W2006509301 @default.
• W1923935917 cites W2017240503 @default.
• W1923935917 cites W2054464463 @default.
• W1923935917 cites W2058938600 @default.
• W1923935917 cites W2060668488 @default.
• W1923935917 cites W2062546181 @default.
• W1923935917 cites W2065624228 @default.
• W1923935917 cites W2068779395 @default.
• W1923935917 cites W2107443927 @default.
• W1923935917 cites W2126501086 @default.
• W1923935917 cites W2132347510 @default.
• W1923935917 cites W2161524242 @default.
• W1923935917 cites W2331068654 @default.
• W1923935917 cites W2767447900 @default.
• W1923935917 cites W4237391818 @default.
• W1923935917 cites W4243694564 @default.
• W1923935917 doi "https://doi.org/10.1111/aos.12772" @default.
• W1923935917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26109209" @default.
• W1923935917 hasPublicationYear "2015" @default.
• W1923935917 type Work @default.
• W1923935917 sameAs 1923935917 @default.
• W1923935917 citedByCount "33" @default.
• W1923935917 countsByYear W19239359172016 @default.
• W1923935917 countsByYear W19239359172017 @default.
• W1923935917 countsByYear W19239359172018 @default.
• W1923935917 countsByYear W19239359172019 @default.
• W1923935917 countsByYear W19239359172020 @default.
• W1923935917 countsByYear W19239359172021 @default.
• W1923935917 countsByYear W19239359172022 @default.
• W1923935917 countsByYear W19239359172023 @default.
• W1923935917 crossrefType "journal-article" @default.
• W1923935917 hasAuthorship W1923935917A5003153143 @default.
• W1923935917 hasAuthorship W1923935917A5038462897 @default.
• W1923935917 hasAuthorship W1923935917A5038801101 @default.
• W1923935917 hasAuthorship W1923935917A5044151832 @default.
• W1923935917 hasAuthorship W1923935917A5053563726 @default.
• W1923935917 hasAuthorship W1923935917A5073684856 @default.
• W1923935917 hasBestOaLocation W19239359171 @default.
• W1923935917 hasConcept C118487528 @default.
• W1923935917 hasConcept C141071460 @default.
• W1923935917 hasConcept C2776268601 @default.
• W1923935917 hasConcept C2776694085 @default.
• W1923935917 hasConcept C2777802072 @default.
• W1923935917 hasConcept C2778257484 @default.
• W1923935917 hasConcept C2778844676 @default.
• W1923935917 hasConcept C2780261187 @default.
• W1923935917 hasConcept C2780347916 @default.
• W1923935917 hasConcept C2780827179 @default.
• W1923935917 hasConcept C2781100027 @default.
• W1923935917 hasConcept C2908732032 @default.
• W1923935917 hasConcept C71924100 @default.
• W1923935917 hasConceptScore W1923935917C118487528 @default.
• W1923935917 hasConceptScore W1923935917C141071460 @default.
• W1923935917 hasConceptScore W1923935917C2776268601 @default.
• W1923935917 hasConceptScore W1923935917C2776694085 @default.
• W1923935917 hasConceptScore W1923935917C2777802072 @default.
• W1923935917 hasConceptScore W1923935917C2778257484 @default.
• W1923935917 hasConceptScore W1923935917C2778844676 @default.
• W1923935917 hasConceptScore W1923935917C2780261187 @default.
• W1923935917 hasConceptScore W1923935917C2780347916 @default.
• W1923935917 hasConceptScore W1923935917C2780827179 @default.
• W1923935917 hasConceptScore W1923935917C2781100027 @default.
• W1923935917 hasConceptScore W1923935917C2908732032 @default.
• W1923935917 hasConceptScore W1923935917C71924100 @default.
• W1923935917 hasIssue "8" @default.
• W1923935917 hasLocation W19239359171 @default.
• W1923935917 hasLocation W19239359172 @default.
• W1923935917 hasOpenAccess W1923935917 @default.
• W1923935917 hasPrimaryLocation W19239359171 @default.
• W1923935917 hasRelatedWork W1631464262 @default.
• W1923935917 hasRelatedWork W1997095687 @default.
• W1923935917 hasRelatedWork W1998879016 @default.
• W1923935917 hasRelatedWork W2093993639 @default.
• W1923935917 hasRelatedWork W2130940350 @default.
• W1923935917 hasRelatedWork W2321207693 @default.
• W1923935917 hasRelatedWork W2802976037 @default.
• W1923935917 hasRelatedWork W2930164715 @default.
• W1923935917 hasRelatedWork W3010879414 @default.
• W1923935917 hasRelatedWork W3147589859 @default.
• W1923935917 hasVolume "93" @default.
• W1923935917 isParatext "false" @default.

• next